This article was first published on Orbex Forex Trading Blog.
This content is synced from the rightful owners. Copyright on text and images belong to the original source.
Shares in US drug-maker Johnson & Johnson are trading a little lower pre-market on Wednesday amidst reports that the company has halted its COVID vaccine trial. The pharmaceutical giant has been running a 60,000 person trial over recent months. However, this week announced that it had ceased the trial after a patient developed an “unexplained illness”.
Study Postponed According to Guidelines
In a statement released yesterday, Johnson & Johnson said:
“We have temporarily paused further dosing in all our Covid-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLE trial, due to an unexplained illness in a study participant.”
While the company maintains that SAEs (serious adverse events), including accidents or illnesses, are an “expected” part of any large clinical study, the firm’s guidelines dictate that they pause the trial to reassess the study.
The phase 3 trial has been active since September, across more than 200 sites globally, including the US. ...
To keep reading this article, please navigate to: Orbex Forex Trading Blog.